

AMENDMENTS TO THE SPECIFICATION

On page 1, before line 3, please replace the priority statement with the following:

The present application is a divisional application of U.S. Serial No. 09/230,405, filed on January 25, 1999, now Patent No. 6,337,074, which has been allowed, which in turn is the U.S. national phase application of PCT International Application No. PCT/GB97/02025, filed 28 July 1997.

On page 34, please replace the paragraph starting on line 16 with the following:

A 3.7 kb fragment spanning nucleotides 76904-80636 of HCMV DNA (Chee et al., 1994) and containing the HCMV UL54 ORF was amplified from a cloned copy of the *HindIII* F fragment of HCMV strain AD169 by PCR. The primers used were:

5'-ATTATCTAGACCGCTATGTTTTTCAACCCG-3' (SEQ ID NO: 15) and
5'-TATATCTAGACATCATCACCGTCCCCAGTCA-3' (SEQ ID NO: 16) which contained *XbaI* sites (underlined). The PCR-generated fragment was cleaved with *XbaI* and initially cloned into the *XbaI* site of pUC19. The *XbaI* fragment was then recloned into the *XbaI* site of the baculovirus transfer vector pAcYMX1 (Stow, 1992) downstream of the polyhedrin promoter to generate plasmid PY54. The entire *XbaI* fragment was sequenced to confirm the presence of the authentic UL54 gene.

On Page 34, please replace the paragraph starting on line 32 and ending on page 35, line 9 with the following:

A 2.7 kb fragment spanning nucleotides 146510-149208 of HCMV DNA (Chee et al., 1994) and containing the HCMV UL102 ORF was amplified from a cloned copy of the

HindIII R fragment of HCMV strain AD169 by PCR. The primers used were 5'-ATTAGGATCCTTCTGTCCGAGGATGACCGCT-3' (SEQ ID NO: 17) and 5'-ATTAGGATCCACGTCACACGCTAAGAGC-3' (SEQ ID NO: 18) which contained *Bam*HI sites (underlined). The PCR-generated fragment was cleaved with *Bam*HI and cloned firstly into the pUC19 *Bam*HI site. The UL102-containing *Bam*HI fragment was then inserted into the *Bam*HI site of transfer vector pAcYM1 (Matsuura et al., 1987) to generate plasmid PY102. The presence of the authentic UL102 gene was confirmed by DNA sequencing of the entire *Bam*HI fragment.

On page 36, please replace the paragraph starting on line 24 and ending on page 37, line 5 with the following:

Antibodies. The hybridoma cell line that secretes monoclonal antibody (MAb) 13815 has been deposited with the European Collection of Cell Cultures (reference number 96072640). Antiserum 113, specific for HSV-1 UL30 (POL), was raised against a peptide corresponding to the C-terminal 15 amino acids of the protein and has been described previously (Marsden et al., 1994). Antiserum 144, specific for HCMV UL54 protein, was raised in rabbits against peptide HLEPAFLPYSVKAHE (SEQ ID NO: 13) that corresponds to the C-terminal 15 amino acids (residues 1226-1240) of UL54. Antiserum 373, specific for HCMV UL102 protein, was raised in rabbits against peptide VLSSALPSVTSSSSG (SEQ ID NO: 14) that corresponds to residues 809-823 of the 873 residue UL102. The peptides were made as multiply antigenic peptides (Tam, 1988) of general structure (peptide sequence)₄K₃A as such peptides have been shown to generate sera with higher anti-protein titers (McLean et al., 1991).

On page 43, please replace the *entire* page with the following:

Table 2 – Peptides used in this study

Peptide	Corresponding residues in UL8	Sequence	M _r ^a	Ic ₅₀ ^b (μM)
1	739-750	YPFDDKMSFLFA (SEQ ID NO: 1)	1480	>250
2	728-750	AGVWGEKGKVVYPFDDKMSFLFA (SEQ ID NO: 2)	2567	>250
3	726-750	VLGVWGEKGKVVYPFDDKMSFLFA (SEQ ID NO: 3)	2779	>250
4	724-750	TGVLGVWGEKGKVVYPFDDKMSFLFA (SEQ ID NO: 4)	2937	>250
5	722-750	VFTGVLAGVWGEKGKVVYPFDDKMSFLFA (SEQ ID NO: 5)	3184	66±22
6	724-738	TGVLGVWGEKGKVV (SEQ ID NO: 6)	1475	>250
7	719-738	IELVFTGVLAGVWGEKGKVV (SEQ ID NO: 7)	2077	2.3±2.2
8	714-728	EILREIELVFTGVLA (SEQ ID NO: 8)	1701	>250
7 J ^c	-	IVEFLKVGFGTEGGVWL VAG (SEQ ID NO: 9)	2077	>20
RT85 ^d	-	VKLWYQLEKEPIVGA (SEQ ID NO:10)	1772	>250

^a Relative molecular mass

^b The concentration of peptide required to reduce POL binding by 50%

^c The same amino acids as peptide 7 but in jumbled order

^d Residues 423-437 of the reverse transcriptase of HIV-1 (strain LAI)

On page 45, please replace the paragraph starting on line 1 and ending just before the word "REFERENCES":

Table 4 - Peptides used in Example 3

Peptide	Corresponding residues in UL102	Sequence	M_r^a	IC_{50}^b (μM)
1	844-873 ^d	DEWVRSLAVDAQHA AKRVASEGLRFFRLNA (SEQ ID NO: 11)	3413	40
2	838-863	TWLEERDEWVRSLAVDAQHAARRVAS (SEQ ID NO: 12)	3052	45
RT85 ^c		VKLWYQLEKEPIVGA (SEQ ID NO: 13)	1772	>200

- a Relative molecular mass
- b The concentration of peptide required to reduce HCMV UL54-binding by 50%
- c Residues 423-437 of the reverse transcriptase of HIV-1 (strain LA1)
- d Contains R to K substitution at residue 859